Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

JCO precision oncology - 1 Mar 2026

Boutros Andrea, Carlino Matteo S, Chaganti Raja, Gonzalez Maria, Lo Serigne N, Pires da Silva Ines, Wong Terence, McKeown Janet, Colebatch Andrew, Rawson Robert V, Páramo Paola Cornejo, Scolyer Richard A, Rizos Helen, Wilmott James S, Long Georgina V, Menzies Alexander M

Abstract excerpt

PURPOSE: Although the clinicopathologic features of BRAF/NRAS-mutant melanoma are well defined, the molecular landscape, clinicopathologic features, and treatment outcomes of BRAF/NRAS wild-type (WT) patients on immune checkpoint inhibitors (ICIs) remain less clear. The MatchMEL study investigated the mutational profile of WT melanoma (Part 1) and examined whether targeted treatments could be matched to specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Membrane Proteins

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 41818644
DOI: 10.1200/PO-25-00886

Genes

BRAF
NRAS
NF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.PMID 41818644Read ↗

Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive AlterationsSemantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.Semantic proximity Read ↗

Driver Mutation Subtypes Differentially Shape Immune Evasion Landscapes in Melanoma: An AI-Driven Inflammatory Pathway Model Implicating CCNE1.Semantic proximity Read ↗

Integrated molecular drivers coordinate biological and clinical states in melanoma.Semantic proximity Read ↗

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.Semantic proximity Read ↗

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity Read ↗

Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment.Semantic proximity Read ↗

Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.Semantic proximity Read ↗

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 ImmunotherapySemantic proximity Read ↗

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.